- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02287766
Metabolic Syndrome Feasibility Study (EPIC-009)
Prognostic Indicators for Metabolic Syndrome as Provided by the EPIC ClearView
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85255
- EPIC Research and Diagnostics
-
Scottsdale, Arizona, United States, 85255
- Integrated Health Institute, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Metabolic Group
Inclusion Criteria:
- Sex: Male or Female
- Age range: 21 to 85
Qualifying Metabolic Syndrome diagnosis(using the National Cholesterol Education Program Adult Treatment Panel (ATP) III definition)(Grundy, 2004)
Subjects will be identified as having Metabolic Syndrome if they meet at least three of the following five criteria:
- Elevated waist circumference: ≥ 102 cm (≥40 inches) in men, ≥ 88 cm (≥35 inches) in women
- Elevated triglycerides: ≥ 150 mg/dL (1.7 mmol/L) or on drug treatment for elevated triglycerides (examples include, but are not limited to, fibrates and nicotinic acid)
- Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in men or < 50 mg/dL (1.3 mmol/L) in women or on drug treatment for reduced HDL-C
- Elevated blood pressure: ≥ 130 mm Hg systolic blood pressure or ≥85 mm Hg diastolic blood pressure or on antihypertensive drug treatment in a patient with a history of hypertension
- Elevated fasting glucose: ≥ 100 mg/dL or on drug treatment for elevated glucose
- The patient or legal representative is able to understand and provide signed consent for the procedure.
Exclusion Criteria:
- Patients < 21years in age or > 85 years in age.
- Inability or unwillingness to provide informed consent.
- Patients with pacemakers or another electrical device implanted somewhere in their body.
- Pregnant women.
- Missing all or part of fingers or cuts/burns on pads of fingers
- Hand tremors or involuntary oscillations of the hands that prevents clear imaging
Control Group:
Inclusion Criteria:
- Sex: Male or Female
- Age range: 21 to 85
- Freedom from qualifying medical diagnoses (control group)
Any one of the following will exclude the subject from participation in the study
- Documented current diagnosis/treatment of cancer (including Sickle Cell Disease)
- Documented current diagnosis/treatment of coronary artery disease or heart attack
- Documented as currently in Renal Failure (chronic or acute) or on renal dialysis
- Documented current diagnosis/treatment for Hepatitis
5 .The patient or legal representative is able to understand and provide signed consent for the procedure.
Exclusion Criteria:
- Patients < 21 years in age or > 85 years in age.
- bility or unwillingness to provide informed consent.
- Patients with pacemakers or another electrical device implanted somewhere in their body.
- Pregnant women.
- Missing all or part of fingers or cuts/burns on pads of fingers
- Hand tremors or involuntary oscillations of the hands that prevents clear imaging
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Control
Men and women ages 21-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following cancer, coronary artery disease or heart attack, renal failure or dialysis, hepatitis, Multiple Sclerosis, or any autoimmune disorder.
|
Metabolic Syndrome Diagnosis Group
Men and women ages 21-85 with at least of at least three of the following (as defined in the protocol) : Elevated waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, elevated fasting glucose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Agreement of ClearView Scan versus Active Diagnosis
Time Frame: At time of ClearView Scan (Single study visit only, with no follow-up. The study endpoint will be reported for day 0, the day of the study visit
|
The EPIC ClearView software produces a Response Scale report that summarizes the electrophysiological measurements associated with organ systems.
The autonomic numbers indicate how the person's stress response is affecting different body systems and the physical numbers reflect physiological function.These measurements will then be compared to metabolic diagnosis.
|
At time of ClearView Scan (Single study visit only, with no follow-up. The study endpoint will be reported for day 0, the day of the study visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Sensitivity and Specificity of ClearView Scan versus Active Diagnosis
Time Frame: Single study visit only, with no follow-up. The study endpoint will be reported for day 0, the day of the study visit
|
Single study visit only, with no follow-up. The study endpoint will be reported for day 0, the day of the study visit
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nancy R Rizzo, PhD, EPIC Research and Diagnostics
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPIC-009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
Mayo ClinicCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia